Gevorg Yaghjyan/LinkedIn
May 20, 2026, 14:13
Gevorg Yaghjyan: Targeting Myostatin in Clinical Trials to Preserve Muscle During Weight Loss
Gevorg Yaghjyan, Project Leader at Parexel, shared a post on LinkedIn:
“Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
GLP-1s deliver weight loss, but trials keep showing a catch: approximately 25-40% of that loss can be lean muscle mass.
Biohaven’s approach: target myostatin in clinical trials to preserve muscle during weight loss.
The hypothesis — better body composition, not just lower weight, drives long-term outcomes.If the data holds, the next obesity trial endpoint might not be pounds lost. It might be muscle retained.
The weight loss race is crowded. The muscle preservation lane is wide open.”
Other posts featuring Gevorg Yaghjyan on Hemostasis Today.
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood
-
Jul 6, 2026, 17:382026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
-
Jul 6, 2026, 17:27Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
-
Jul 6, 2026, 17:15Sanchit Sharma։ Continuous Anticoagulation in PVT with Varices